Preliminary results of the global audit of treatment of refractory XXXX .

@entity1 @entity410 @entity3652 @entity1875 @entity302 @entity230 @entity1363 @entity159
UNASSIGNED: The treatment of refractory and super refractory @entity159 is a "terra incognita" from the point of view of evidence-based medicine. As randomized or controlled studies that are sufficiently powered are not feasible in relation to the many therapies and treatment approaches available, we carried out an online multinational audit (registry) in which neurologists or intensivists caring for @entity1 with @entity159 may prospectively enter @entity1 who required general anesthesia to control the @entity159 ( @entity159 ). To date, 488 cases from 44 different countries have been collected. Most of the @entity1 had no history of @entity302 and had a cryptogenic etiology. First-line treatment was delayed and not in line with current guidelines. The most widely used anesthetic of first choice was @entity1363 (59%), followed by @entity1875 and barbiturates. @entity3652 was used in most severe cases. Other therapies were administered in 35% of the cases, mainly @entity230 and immunotherapy. @entity410 control was achieved in 74% of the @entity1 . Twenty-two percent of @entity1 died during treatment, and four percent had treatment actively withdrawn because of an anticipated poor outcome. The neurological outcome was good in 36% and poor in 39.3% of cases, while 25% died during hospitalization. Factors that positively influenced outcome were younger age, history of @entity302 , and low number of different anesthetics tried. This article is part of a Special Issue entitled " @entity159 ".
